Top

Published in:

Open Access 01-12-2021 | Alzheimer's Disease | Research

APOE genotype dependent molecular abnormalities in the cerebrovasculature of Alzheimer’s disease and age-matched non-demented brains

Authors: Joseph O. Ojo, Jon M. Reed, Gogce Crynen, Prashanthi Vallabhaneni, James Evans, Benjamin Shackleton, Maximillian Eisenbaum, Charis Ringland, Anastasia Edsell, Michael Mullan, Fiona Crawford, Corbin Bachmeier

Published in: Molecular Brain | Issue 1/2021

Abstract

Cerebrovascular dysfunction is a hallmark feature of Alzheimer's disease (AD). One of the greatest risk factors for AD is the apolipoprotein E4 (E4) allele. The APOE4 genotype has been shown to negatively impact vascular amyloid clearance, however, its direct influence on the molecular integrity of the cerebrovasculature compared to other APOE variants (APOE2 and APOE3) has been largely unexplored. To address this, we employed a 10-plex tandem isobaric mass tag approach in combination with an ultra-high pressure liquid chromatography MS/MS (Q-Exactive) method, to interrogate unbiased proteomic changes in cerebrovessels from AD and healthy control brains with different APOE genotypes. We first interrogated changes between healthy control cases to identify underlying genotype specific effects in cerebrovessels. EIF2 signaling, regulation of eIF4 and 70S6K signaling and mTOR signaling were the top significantly altered pathways in E4/E4 compared to E3/E3 cases. Oxidative phosphorylation, EIF2 signaling and mitochondrial dysfunction were the top significant pathways in E2E2 vs E3/E3cases. We also identified AD-dependent changes and their interactions with APOE genotype and found the highest number of significant proteins from this interaction was observed in the E3/E4 (192) and E4/E4 (189) cases. As above, EIF2, mTOR signaling and eIF4 and 70S6K signaling were the top three significantly altered pathways in E4 allele carriers (i.e. E3/E4 and E4/E4 genotypes). Of all the cerebrovascular cell-type specific markers identified in our proteomic analyses, endothelial cell, astrocyte, and smooth muscle cell specific protein markers were significantly altered in E3/E4 cases, while endothelial cells and astrocyte specific protein markers were altered in E4/E4 cases. These proteomic changes provide novel insights into the longstanding link between APOE4 and cerebrovascular dysfunction, implicating a role for impaired autophagy, ER stress, and mitochondrial bioenergetics. These APOE4 dependent changes we identified could provide novel cerebrovascular targets for developing disease modifying strategies to mitigate the effects of APOE4 genotype on AD pathogenesis.

Available only for authorised users

de la Torre J. The vascular hypothesis of Alzheimer’s Disease: a key to preclinical prediction of dementia using neuroimaging. Mecocci P, editor. J Alzheimers Dis. 2018;63:35–52. https://doi.org/10.3233/JAD-180004

De la Torre JC, Mussivand T. Can disturbed brain microcirculation cause Alzheimer’s disease? Neurol Res. 1993;15:146–53. https://doi.org/10.1080/01616412.1993.11740127.CrossRefPubMed

Di Marco LY, Venneri A, Farkas E, Evans PC, Marzo A, Frangi AF. Vascular dysfunction in the pathogenesis of Alzheimer’s disease—a review of endothelium-mediated mechanisms and ensuing vicious circles. Neurobiol Dis. 2015;82:593–606.PubMedCrossRef

Binnewijzend MAA, Benedictus MR, Kuijer JPA, van der Flier WM, Teunissen CE, Prins ND, et al. Cerebral perfusion in the predementia stages of Alzheimer’s disease. Eur Radiol. 2016;26:506–14.PubMedCrossRef

Hays CC, Zlatar ZZ, Wierenga CE. The utility of cerebral blood flow as a biomarker of preclinical Alzheimer’s disease. Cell Mol Neurobiol. 2016;36:167–79. https://doi.org/10.1007/s10571-015-0261-z.CrossRefPubMedPubMedCentral

Attems J, Jellinger K, Thal DR, Van Nostrand W. Review: sporadic cerebral amyloid angiopathy. Neuropathol Appl Neurobiol. 2011;37:75–93.PubMedCrossRef

Snowdon DA. Aging and Alzheimer’s disease: Lessons from the Nun Study. Gerontologist. 1997;37:150–6. https://doi.org/10.1093/geront/37.2.150.CrossRefPubMed

Snowdon DA. Brain infarction and the clinical expression of Alzheimer disease: the Nun Study. JAMA J Am Med Assoc. 1997;277:813–7. https://doi.org/10.1001/jama.277.10.813.CrossRef

Nagy Z, Esiri MM, Jobst KA, Morris JH, King EMF, Mcdonald B, et al. The effects of additional pathology on the cognitive deficit in Alzheimer disease. J Neuropathol Exp Neurol. 1997;56:165–70. https://doi.org/10.1097/00005072-199702000-00007.CrossRefPubMed

10.

Roher AE, Esh C, Rahman A, Kokjohn TA, Beach TG. Atherosclerosis of cerebral arteries in Alzheimer disease. Stroke. 2004;35:2623–7.PubMedCrossRef

11.

Yarchoan M, Xie SX, Kling MA, Toledo JB, Wolk DA, Lee EB, et al. Cerebrovascular atherosclerosis correlates with Alzheimer pathology in neurodegenerative dementias. Brain. 2012;135:3749–56.PubMedPubMedCentralCrossRef

12.

Beach TG, Wilson JR, Sue LI, Newell A, Poston M, Cisneros R, et al. Circle of Willis atherosclerosis: association with Alzheimer’s disease, neuritic plaques and neurofibrillary tangles. Acta Neuropathol. 2007;113:13–21. https://doi.org/10.1007/s00401-006-0136-y.CrossRefPubMed

13.

Østergaard L, Aamand R, Gutiérrez-Jiménez E, Ho YCL, Blicher JU, Madsen SM, et al. The capillary dysfunction hypothesis of Alzheimer’s disease. Neurobiol Aging. 2013;34:1018–31.PubMedCrossRef

14.

Kimura T, Hashimura T, Miyakawa T. Observations of microvessels in the brain with Alzheimer’s disease by the scanning electron microscopy. Psychiatry Clin Neurosci. 1991;45:671–6.CrossRef

15.

Hashimura T, Kimura T, Miyakawa T. Morphological changes of blood vessels in the brain with Alzheimer’s disease. Psychiatry Clin Neurosci. 1991;45:661–5. https://doi.org/10.1111/j.1440-1819.1991.tb01187.x.CrossRef

16.

Miyakawa T, Kuramoto R. Ultrastructural study of senile plaques and microvessels in the brain with Alzheimer’s disease and Down’s syndrome. Ann Med. 1989;21:99–102.PubMedCrossRef

17.

Farkas E, De Jong GI, De Vos RAI, Jansen Steur ENH, Luiten PGM. Pathological features of cerebral cortical capillaries are doubled in Alzheimer’s disease and Parkinson’s disease. Acta Neuropathol. 2000;100:395–402. https://doi.org/10.1007/s004010000195.CrossRefPubMed

18.

Deane R, Zlokovic B. Role of the blood-brain barrier in the pathogenesis of Alzheimers disease. Curr Alzheimer Res. 2007;4:191–7.PubMedCrossRef

19.

Miyakawa T. Vascular pathology in Alzheimer’s disease. Psychogeriatrics. 2010;10:39–44. https://doi.org/10.1111/j.1479-8301.2009.00294.x.CrossRefPubMed

20.

Erkinjuntti T, Román G, Gauthier S, Feldman H, Rockwood K. Emerging therapies for vascular dementia and vascular cognitive impairment. Stroke. 2004;35:1010–7. https://doi.org/10.1161/01.STR.0000120731.88236.33.CrossRefPubMed

21.

Kalaria RN. Comparison between Alzheimer’s disease and vascular dementia: implications for treatment. Neurol Res. 2003;25:661–4. https://doi.org/10.1179/016164103101201968.CrossRefPubMed

22.

Custodio N, Montesinos R, Lira D, Herrera-Pérez E, Bardales Y, Valeriano-Lorenzo L. Demência mista: Revisão das evidências. Dement e Neuropsychol. 2017;11:364–70.CrossRef

23.

Govindpani K, McNamara LG, Smith NR, Vinnakota C, Waldvogel HJ, Faull RL, et al. Vascular dysfunction in Alzheimer’s disease: a prelude to the pathological process or a consequence of it? J Clin Med. 2019;8:651.PubMedCentralCrossRef

24.

Mosconi L. Brain glucose metabolism in the early and specific diagnosis of Alzheimer’s disease: FDG-PET studies in MCI and AD. Eur J Nucl Med Mol Imaging. 2005;32:486–510. https://doi.org/10.1007/s00259-005-1762-7.CrossRefPubMed

25.

Mawuenyega KG, Sigurdson W, Ovod V, Munsell L, Kasten T, Morris JC, et al. Decreased clearance of CNS β-amyloid in Alzheimer’s disease. Science. 2010;330:1774. https://doi.org/10.1126/science.1197623.CrossRefPubMedPubMedCentral

26.

Ince PG. Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. Lancet. 2001;357:169–75.CrossRef

27.

Thal DR, Ghebremedhin E, Orantes M, Wiestler OD. Vascular pathology in Alzheimer disease: correlation of cerebral amyloid angiopathy and arteriosclerosis/lipohyalinosis with cognitive decline. J Neuropathol Exp Neurol. 2003;62:1287–301.PubMedCrossRef

28.

Tian J, Shi J, Bailey K, Mann DMA. Relationships between arteriosclerosis, cerebral amyloid angiopathy and myelin loss from cerebral cortical white matter in Alzheimer’s disease. Neuropathol Appl Neurobiol. 2004;30:46–56.PubMedCrossRef

29.

Kalback W, Esh C, Castaño EM, Rahman A, Kokjohn T, Luehrs DC, et al. Atherosclerosis, vascular amyloidosis and brain hypoperfusion in the pathogenesis of sporadic Alzheimer’s disease. Neurol Res. 2004;26:525–39.PubMedCrossRef

30.

Liu CC, Kanekiyo T, Xu H, Bu G. Apolipoprotein e and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol. 2013;9:106–18.PubMedPubMedCentralCrossRef

31.

El SS, Costanian C, Kassir R, Visvkis-Siest S, Bissar-Tadmouri N. APOE genotypes in Lebanon: distribution and association with hypercholesterolemia and Alzheimer’s disease. Per Med. 2019;16:15–23. https://doi.org/10.2217/pme-2018-0067.CrossRef

32.

Chartier-hariln MC, Parfitt M, Legrain S, Pérez-tur J, Brousseau T, Evans A, et al. Apolipoprotein e, ɛ4 allele as a major risk factor for sporadic early and late-onset forms of alzheimer’s disease: analysis of the 19q13.2 chromosomal region. Hum Mol Genet. 1994;3:569–74. https://doi.org/10.1093/hmg/3.4.569.CrossRef

33.

Mahley RW, Rall SC. Apolipoprotein E: Far more than a lipid transport protein. Annu Rev Genomics Hum Genet. 2000;1:507–37. https://doi.org/10.1146/annurev.genom.1.1.507.CrossRefPubMed

34.

Yamazaki Y, Zhao N, Caulfield TR, Liu CC, Bu G. Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies. Nat Rev Neurol. 2019;15:501–18.PubMedPubMedCentralCrossRef

35.

Oh U, Gupta R, Krakauer JW, Khandji AG, Chin SS, Elkind MSV. Reversible leukoencephalopathy associated with cerebral amyloid angiopathy. Neurology. 2004;62:494–7. https://doi.org/10.1212/01.WNL.0000106951.94624.DF.CrossRefPubMed

36.

Kinnecom C, Lev MH, Wendell L, Smith EE, Rosand J, Frosch MP, et al. Course of cerebral amyloid angiopathy-related inflammation. Neurology. 2007;68:1411–6.PubMedCrossRef

37.

Lim SY, Wesley Thevathasan A, Gonzales M, Mitchell PJ, Evans A. Vasogenic oedema with no mass lesion. J Clin Neurosci. 2008;15:9.CrossRef

38.

Greenberg SM, William Rebeck G, Vonsattel JPG, Gomez-Isla T, Hyman BT. Apolipoprotein E ϵ4 and cerebral hemorrhage associated with amyloid angiopathy. Ann Neurol. 1995;38:254–9. https://doi.org/10.1002/ana.410380219.CrossRefPubMed

39.

Alonzo NC, Hyman BT, Rebeck GW, Greenberg SM. Progression of cerebral amyloid angiopathy: accumulation of amyloid- β40 in affected vessels. J Neuropathol Exp Neurol. 1998;57:353–9. https://doi.org/10.1097/00005072-199804000-00008.CrossRefPubMed

40.

Utter S, Tamboli IY, Walter J, Upadhaya AR, Birkenmeier G, Pietrzik CU, et al. Cerebral small vessel disease-induced apolipoprotein e leakage is associated with alzheimer disease and the accumulation of amyloid β-protein in perivascular astrocytes. J Neuropathol Exp Neurol. 2008;67:842–56. https://doi.org/10.1097/NEN.0b013e3181836a71.CrossRefPubMed

41.

Luo X, Jiaerken Y, Yu X, Huang P, Qiu T, Jia Y, et al. Associations between APOE genotype and cerebral small-vessel disease: a longitudinal study. Oncotarget. 2017;8:44477–89.PubMedPubMedCentralCrossRef

42.

Bell RD, Winkler EA, Singh I, Sagare AP, Deane R, Wu Z, et al. Apolipoprotein e controls cerebrovascular integrity via cyclophilin A. Nature. 2012;485:512–6. https://doi.org/10.1038/nature11087.CrossRefPubMedPubMedCentral

43.

Zhang Z, Chen XY, Baum L, Ng HK, Mok V, Wong KS. Association between the apolipoprotein e gene polymorphism and atherosclerotic middle cerebral artery stenosis. Neurologist. 2018;23:47–50.PubMedCrossRef

44.

Kosunen O, Talasniemi S, Lehtovirta M, Heinonen O, Helisalmi SM, Mannermaa AM, et al. Relation of coronary atherosclerosis and apolipoprotein e genotypes in alzheimer patients. Stroke. 1995;26:743–8.PubMedCrossRef

45.

Thambisetty M, Beason-Held L, An Y, Kraut MA, Resnick SM. APOE ε4 genotype and longitudinal changes in cerebral blood flow in normal aging. Arch Neurol. 2010;67:93–8.PubMedPubMedCentralCrossRef

46.

Farrall AJ, Wardlaw JM. Blood-brain barrier: ageing and microvascular disease—systematic review and meta-analysis. Neurobiol Aging. 2009;30:337–52.PubMedCrossRef

47.

Montagne A, Nation DA, Sagare AP, Barisano G, Sweeney MD, Chakhoyan A, et al. APOE4 leads to blood–brain barrier dysfunction predicting cognitive decline. Nature. 2020;581:71–6.PubMedPubMedCentralCrossRef

48.

Salloway S, Gur T, Berzin T, Zipser B, Correia S, Hovanesian V, et al. Effect of APOE genotype on microvascular basement membrane in Alzheimer’s disease. J Neurol Sci. 2002;203:183–7.PubMedCrossRef

49.

Dickstein DL, Walsh J, Brautigam H, Stockton SD, Gandy S, Hof PR. Role of vascular risk factors and vascular dysfunction in Alzheimer’s disease. Mt Sinai J Med. 2010;77:82–102. https://doi.org/10.1002/msj.20155.CrossRefPubMedPubMedCentral

50.

Johnson ECB, Dammer EB, Duong DM, Ping L, Zhou M, Yin L, et al. Large-scale proteomic analysis of Alzheimer’s disease brain and cerebrospinal fluid reveals early changes in energy metabolism associated with microglia and astrocyte activation. Nat Med. 2020;26:769–80.PubMedPubMedCentralCrossRef

51.

Johnson ECB, Dammer EB, Duong DM, Yin L, Thambisetty M, Troncoso JC, et al. Deep proteomic network analysis of Alzheimer’s disease brain reveals alterations in RNA binding proteins and RNA splicing associated with disease. Mol Neurodegener. 2018. https://doi.org/10.1186/s13024-018-0282-4.CrossRefPubMedPubMedCentral

52.

Bai B, Wang X, Li Y, Chen PC, Yu K, Dey KK, et al. Deep multilayer brain proteomics identifies molecular networks in Alzheimer’s disease progression. Neuron. 2020;105:975-991.e7.PubMedPubMedCentralCrossRef

53.

Zhang J, Keene CD, Pan C, Montine KS, Montine TJ. Proteomics of human neurodegenerative diseases. J Neuropathol Exp Neurol. 2008;67:923–32.PubMedCrossRef

54.

Manousopoulou A, Gatherer M, Smith C, Nicoll JAR, Woelk CH, Johnson M, et al. Systems proteomic analysis reveals that clusterin and tissue inhibitor of metalloproteinases 3 increase in leptomeningeal arteries affected by cerebral amyloid angiopathy. Neuropathol Appl Neurobiol. 2017;43:492–504.PubMedCrossRef

55.

Hondius DC, Eigenhuis KN, Morrema THJ, van der Schors RC, van Nierop P, Bugiani M, et al. Proteomics analysis identifies new markers associated with capillary cerebral amyloid angiopathy in Alzheimer’s disease. Acta Neuropathol Commun. 2018;6:46. https://doi.org/10.1186/s40478-018-0540-2.CrossRefPubMedPubMedCentral

56.

Badhwar A, Brown R, Stanimirovic DB, Haqqani AS, Hamel E. Proteomic differences in brain vessels of Alzheimer’s disease mice: normalization by PPARI 3 agonist pioglitazone. J Cereb Blood Flow Metab. 2017;37:1120–36.PubMedCrossRef

57.

Pearson A, Ajoy R, Crynen G, Reed JM, Algamal M, Mullan M, et al. Molecular abnormalities in autopsied brain tissue from the inferior horn of the lateral ventricles of nonagenarians and Alzheimer disease patients. BMC Neurol. 2020. https://doi.org/10.1186/s12883-020-01849-3.CrossRefPubMedPubMedCentral

58.

Vonsattel JPG, Myers RH, Tessa Hedley-Whyte E, Ropper AH, Bird ED, Richardson EP. Cerebral amyloid angiopathy without and with cerebral hemorrhages: a comparative histological study. Ann Neurol. 1991;30:637–49.PubMedCrossRef

59.

Bachmeier C, Shackleton B, Ojo J, Paris D, Mullan M, Crawford F. Apolipoprotein E isoform-specific effects on lipoprotein receptor processing. NeuroMolecular Med. 2014;16(4):686–96. https://doi.org/10.1007/s12017-014-8318-6.

60.

Ojo J, Eisenbaum M, Shackleton B, Lynch C, Joshi U, Saltiel N, et al. Mural cell dysfunction leads to altered cerebrovascular tau uptake following repetitive head trauma. Neurobiol Dis. 2021;150(105237):S0969996120305131.

61.

Ojo JO, Crynen G, Algamal M, Vallabhaneni P, Leary P, Mouzon B, et al. Unbiased proteomic approach identifies pathobiological profiles in the brains of preclinical models of repetitive mild traumatic brain injury, tauopathy, and amyloidosis. ASN Neuro. 2020;12:1759091420914768. https://doi.org/10.1177/1759091420914768.CrossRefPubMedPubMedCentral

62.

Vizcaíno JA, Csordas A, Del-Toro N, Dianes JA, Griss J, Lavidas I, et al. 2016 update of the PRIDE database and its related tools. Nucleic Acids Res. 2016;44:D447–56.PubMedCrossRef

63.

Krämer A, Green J, Pollard J, Tugendreich S. Causal analysis approaches in ingenuity pathway analysis. Bioinformatics. 2014;30:523–30.PubMedCrossRef

64.

Nicoll JAR, Burnett C, Love S, Graham DI, Dewar D, Ironside JW, et al. High frequency of apolipoprotem E ε2 allele in hemorrhage due to cerebral amyloid angiopathy. Ann Neurol. 1997;41:716–21.PubMedCrossRef

65.

McCarron MO, Nicoll JAR. High frequency of apolipoprotein E ε2 allele is specific for patients with cerebral amyloid angiopathy-related haemorrhage. Neurosci Lett. 1998;247:45–8.PubMedCrossRef

66.

Nicoll JAR, McCarron MO. APOE gene polymorphism as a risk factor for cerebral amyloid angiopathy-related hemorrhage. Amyloid. 2001;8:51–5.PubMed

67.

Schilling S, DeStefano AL, Sachdev PS, Choi SH, Mather KA, DeCarli CD, et al. APOE genotype and MRI markers of cerebrovascular disease. Neurology. 2013;3:292–300.CrossRef

68.

Huang Y, Schwendner SW, Rall SC, Mahley RW. Hypolipidemic and hyperlipidemic phenotypes in transgenic mice expressing human apolipoprotein E2. J Biol Chem. 1996;271:29146–51.PubMedCrossRef

69.

Rasmussen KL, Tybjærg-Hansen A, Nordestgaard BG, Frikke-Schmidt R. Plasma levels of apolipoprotein E, APOE genotype, and all-cause and cause-specific mortality in 105 949 individuals from a white general population cohort. Eur Heart J. 2019;40:2813–24.PubMedPubMedCentralCrossRef

70.

Sebastiani P, Raghavachari N. Neuroprotective effect of apoe2: evidence and implication for cognitive aging. Innov Aging. 2019;3:S620.PubMedCentralCrossRef

71.

Shinohara M, Kanekiyo T, Tachibana M, Kurti A, Shinohara M, Fu Y, et al. Apoe2 is associated with longevity independent of alzheimer’s disease. Elife. 2020. https://doi.org/10.7554/eLife.62199.CrossRefPubMedPubMedCentral

72.

Lin AL, Parikh I, Yanckello LM, White RS, Hartz AMS, Taylor CE, et al. APOE genotype-dependent pharmacogenetic responses to rapamycin for preventing Alzheimer’s disease. Neurobiol. Dis. 2020.

73.

Lin AL, Butterfield DA, Richardson A. mTOR: Alzheimer’s disease prevention for APOE4 carriers. Oncotarget. 2016;29:44873.CrossRef

74.

Ohno M. Roles of eIF2α kinases in the pathogenesis of Alzheimer’s disease. Front Mol Neurosci. 2014;7:22.PubMedPubMedCentralCrossRef

75.

Oliveira MM, Lourenco MV. Integrated stress response: Connecting apoE4 to memory impairment in Alzheimer’s disease. J Neurosci. 2016;36:4.CrossRef

76.

Segev Y, Michaelson DM, Rosenblum K. ApoE ε4 is associated with eIF2α phosphorylation and impaired learning in young mice. Neurobiol Aging. 2013;34:863.PubMedCrossRef

77.

Dai J, Johnson ECB, Dammer EB, Duong DM, Gearing M, Lah JJ, et al. Effects of APOE genotype on brain proteomic network and cell type changes in Alzheimer’s disease. Front Mol Neurosci. 2018. https://doi.org/10.3389/fnmol.2018.00454.CrossRefPubMedPubMedCentral

78.

Nelson PT, Pious NM, Jicha GA, Wilcock DM, Fardo DW, Estus S, et al. APOE-ε2 and APOE ε4 correlate with increased amyloid accumulation in cerebral vasculature. J Neuropathol Exp Neurol. 2013;72:708–15.PubMedCrossRef

79.

Rannikmäe K, Kalaria RN, Greenberg SM, Chui HC, Schmitt FA, Samarasekera N, et al. APOE associations with severe CAA-associated vasculopathic changes: collaborative meta-analysis. J Neurol Neurosurg Psychiatry. 2014;85:300–5.PubMedCrossRef

80.

McCarron MO, Nicoll JAR. Apolipoprotein E genotype and cerebral amyloid angiopathy-related hemorrhage. Ann N Y Acad Sci. 2000;903:176–9.PubMedCrossRef

81.

Hawkes CA, Sullivan PM, Hands S, Weller RO, Nicoll JAR, Carare RO. Disruption of arterial perivascular drainage of amyloid-β from the brains of mice expressing the human APOE ε4 allele. PLoS One. 2012;7:e41636.PubMedPubMedCentralCrossRef

82.

Thal DR, Griffin WST, de Vos RAI, Ghebremedhin E. Cerebral amyloid angiopathy and its relationship to Alzheimer’s disease. Acta Neuropathol. 2008;6:599–609.CrossRef

83.

Deane R, Sagare A, Hamm K, Parisi M, Lane S, Finn MB, et al. apoE isoform-specific disruption of amyloid β peptide clearance from mouse brain. J Clin Invest. 2008;118:4002–13.PubMedPubMedCentralCrossRef

84.

Thal DR, Larionov S, Abramowski D, Wiederhold KH, Van Dooren T, Yamaguchi H, et al. Occurrence and co-localization of amyloid β-protein and apolipoprotein E in perivascular drainage channels of wild-type and APP-transgenic mice. Neurobiol Aging. 2007;28:1221–30.PubMedCrossRef

85.

Rolyan H, Feike AC, Upadhaya AR, Waha A, Van Dooren T, Haass C, et al. Amyloid-β protein modulates the perivascular clearance of neuronal apolipoprotein e in mouse models of Alzheimer’s disease. J Neural Transm. 2011;118:699–712.PubMedCrossRef

86.

Zekonyte J, Sakai K, Nicoll JAR, Weller RO, Carare RO. Quantification of molecular interactions between ApoE, amyloid-beta (Aβ) and laminin: relevance to accumulation of Aβ in Alzheimer’s disease. Biochim Biophys Acta Mol Basis Dis. 2016;1862:1047–53.CrossRef

87.

Yamaguchi H, Ishiguro K, Sugihara S, Nakazato Y, Kawarabayashi T, Sun X, et al. Presence of apolipoprotein E on extracellular neurofibrillary tangles and on meningeal blood vessels precedes the Alzheimer β-amyloid deposition. Acta Neuropathol. 1994;88:413–9.PubMedCrossRef

88.

Fullerton SM, Shirman GA, Strittmatter WJ, Matthew WD. Impairment of the blood-nerve and blood-brain barriers in apolipoprotein E knockout mice. Exp Neurol. 2001;169:13–22.PubMedCrossRef

89.

Donahue JE, Johanson CE. Apolipoprotein E, amyloid-β, and blood-brain barrier permeability in Alzheimer disease. J Neuropathol Exp Neurol. 2008;67:261–70. https://doi.org/10.1097/NEN.0b013e31816a0dc8.CrossRefPubMed

90.

Kim J, Basak JM, Holtzman DM. The role of apolipoprotein E in Alzheimer’s Disease. Neuron. 2009;63:287–303.PubMedPubMedCentralCrossRef

91.

Shinohara M, Petersen RC, Dickson DW, Bu G. Brain regional correlation of amyloid-β with synapses and apolipoprotein E in non-demented individuals: potential mechanisms underlying regional vulnerability to amyloid-β accumulation. Acta Neuropathol. 2013;125:535–47. https://doi.org/10.1007/s00401-013-1086-9.CrossRefPubMedPubMedCentral

92.

Pirttilä T, Soininen H, Heinonen O, Lehtimäki T, Bogdanovic N, Paljärvi L, et al. Apolipoprotein E (apoE) levels in brains from Alzheimer disease patients and controls. Brain Res. 1996;722:71–7.PubMedCrossRef

93.

Lambert JC, Pérez-Tur J, Dupire MJ, Galasko D, Mann D, Amouyel P, et al. Distortion of allelic expression of apolipoprotein E in Alzheimer’s disease. Hum Mol Genet. 1997;6:2151–4.PubMedCrossRef

94.

Harr SD, Uint L, Hollister R, Hyman BT, Mendez AJ. Brain expression of apolipoproteins E, J, and A-I in Alzheimer’s disease. J Neurochem. 1996;66:2429–35.PubMedCrossRef

95.

Growdon JH, Locascio JJ, Corkin S, Gomez-Isla T, Hyman BT. Apolipoprotein E genotype does not influence rates of cognitive decline in Alzheimer’s disease. Neurology. 1996;47:444–8.PubMedCrossRef

96.

Bray NJ, Jehu L, Moskvina V, Buxbaum JD, Dracheva S, Haroutunian V, et al. Allelic expression of APOE in human brain: effects of epsilon status and promoter haplotypes. Hum Mol Genet. 2004;13:2885–92.PubMedCrossRef

97.

Bertrand P, Poirier J, Oda T, Finch CE, Pasinetti GM. Association of apolipoprotein E genotype with brain levels of apolipoprotein E and apolipoprotein J (clusterin) in Alzheimer disease. Brain Res Mol Brain Res. 1995;33:174–8.PubMedCrossRef

98.

Beffert U, Cohn JS, Petit-Turcotte C, Tremblay M, Aumont N, Ramassamy C, et al. Apolipoprotein E and β-amyloid levels in the hippocampus and frontal cortex of Alzheimer’s disease subjects are disease-related and apolipoprotein E genotype dependent. Brain Res. 1999;843:87–94.PubMedCrossRef

99.

Halliday MR, Rege SV, Ma Q, Zhao Z, Miller CA, Winkler EA, et al. Accelerated pericyte degeneration and blood-brain barrier breakdown in apolipoprotein E4 carriers with Alzheimer’s disease. J Cereb Blood Flow Metab. 2016;36:216–27. https://doi.org/10.1038/jcbfm.2015.44.CrossRefPubMedPubMedCentral

100.

Nation DA, Sweeney MD, Montagne A, Sagare AP, D’Orazio LM, Pachicano M, et al. Blood–brain barrier breakdown is an early biomarker of human cognitive dysfunction. Nat Med. 2019;25:270–6.PubMedPubMedCentralCrossRef

101.

Nortley R, Korte N, Izquierdo P, Hirunpattarasilp C, Mishra A, Jaunmuktane Z, et al. Amyloid b oligomers constrict human capillaries in Alzheimer’s disease via signaling to pericytes. Science. 2019;365:6450.CrossRef

102.

Khennouf L, Gesslein B, Brazhe A, Octeau JC, Kutuzov N, Khakh BS, et al. Active role of capillary pericytes during stimulation-induced activity and spreading depolarization. Brain. 2018;141:2032–46.PubMedPubMedCentralCrossRef

103.

Hamilton NB. Pericyte-mediated regulation of capillary diameter: a component of neurovascular coupling in health and disease. Front Neuroenergetics. 2010. https://doi.org/10.3389/fnene.2010.00005/abstract.CrossRefPubMedPubMedCentral

104.

Shi Y, Manis M, Long J, Wang K, Sullivan PM, Serrano JR, et al. Microglia drive APOE-dependent neurodegeneration in a tauopathy mouse model. J Exp Med. 2019;216:2546–61.PubMedPubMedCentralCrossRef

105.

Rodriguez GA, Tai LM, LaDu MJ, Rebeck GW. Human APOE4 increases microglia reactivity at Aβ plaques in a mouse model of Aβ deposition. J Neuroinflammation. 2014;11:111.PubMedPubMedCentralCrossRef

106.

Vitek MP, Brown CM, Colton CA. APOE genotype-specific differences in the innate immune response. Neurobiol Aging. 2009;30:1350–60.PubMedCrossRef

107.

Zhao L, Lin S, Bales KR, Gelfanova V, Koger D, DeLong C, et al. Macrophage-mediated degradation of β-amyloid via an apolipoprotein e isoform-dependent mechanism. J Neurosci. 2009;29:3603–12.PubMedPubMedCentralCrossRef

108.

Lin YT, Seo J, Gao F, Feldman HM, Wen HL, Penney J, et al. APOE4 causes widespread molecular and cellular alterations associated with Alzheimer’s disease phenotypes in human iPSC-derived brain cell types. Neuron. 2018;98:1141-1154.e7.PubMedPubMedCentralCrossRef

109.

Shi Y, Yamada K, Liddelow SA, Smith ST, Zhao L, Luo W, et al. ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy. Nature. 2017;549:523–7. https://doi.org/10.1038/nature24016.CrossRefPubMedPubMedCentral

110.

Krasemann S, Madore C, Cialic R, Baufeld C, Calcagno N, El Fatimy R, et al. The TREM2-APOE pathway drives the transcriptional phenotype of dysfunctional microglia in neurodegenerative diseases. Immunity. 2017;47:566-581.e9.PubMedPubMedCentralCrossRef

111.

Shi Y, Yamada K, Liddelow SA, Smith ST, Zhao L, Luo W, et al. ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy, Alzheimer’s Disease Neuroimaging Initiative. Nature. 2017;549:523.PubMedPubMedCentralCrossRef

112.

Liu T, Zhu B, Liu Y, Zhang X, Yin J, Li X, et al. Multi-omic comparison of Alzheimer’s variants in human ESC-derived microglia reveals convergence at APOE. J Exp Med. 2020. https://doi.org/10.1084/jem.20200474.CrossRefPubMedPubMedCentral

113.

Cruz Hernández JC, Bracko O, Kersbergen CJ, Muse V, Haft-Javaherian M, Berg M, et al. Neutrophil adhesion in brain capillaries reduces cortical blood flow and impairs memory function in Alzheimer’s disease mouse models. Nat Neurosci. 2019;22:413–20.PubMedPubMedCentralCrossRef

Title: APOE genotype dependent molecular abnormalities in the cerebrovasculature of Alzheimer’s disease and age-matched non-demented brains
Authors: Joseph O. Ojo
Jon M. Reed
Gogce Crynen
Prashanthi Vallabhaneni
James Evans
Benjamin Shackleton
Maximillian Eisenbaum
Charis Ringland
Anastasia Edsell
Michael Mullan
Fiona Crawford
Corbin Bachmeier
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Alzheimer's Disease
Alzheimer's Disease
Published in: Molecular Brain / Issue 1/2021
Electronic ISSN: 1756-6606
DOI: https://doi.org/10.1186/s13041-021-00803-9

Keynote webinar | Spotlight on medication adherence

Springer Medicine

APOE genotype dependent molecular abnormalities in the cerebrovasculature of Alzheimer’s disease and age-matched non-demented brains

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2021

The physiological role of Homer2a and its novel short isoform, Homer2e, in NMDA receptor-mediated apoptosis in cerebellar granule cells

The novel multiple sclerosis susceptibility gene ATXN1 regulates B cell receptor signaling in B-1a cells

Meningitic Escherichia coli α-hemolysin aggravates blood–brain barrier disruption via targeting TGFβ1-triggered hedgehog signaling

Arginine vasopressin in the medial amygdala causes greater post-stress recruitment of hypothalamic vasopressin neurons

Autophagy activity contributes to the impairment of social recognition in Epac2−/− mice

Correction to: Antibiotics-induced intestinal dysbacteriosis caused behavioral alternations and neuronal activation in different brain regions in mice